Pharos Capital Launches Verdi Oncology through Horizon Oncology Acquisition

We represented Pharos Capital Group in its acquisition of Horizon Oncology. The acquisition marks the launch of Verdi Oncology, Inc., an oncology practice and clinical research management company. Financial terms of the transaction were not publicly disclosed.

Horizon Oncology offers a wide range of comprehensive cancer services to patients, including advanced technological options, premier clinical expertise and cutting edge clinical trials opportunities, with a focus on early phase trials.

Pharos Capital Group is an SEC Registered Investment Advisor. As of March 2018, Pharos has invested in 51 companies and currently has over $690 million of private equity assets under management.

You Also May Be Interested In:

  • Representation of Tennessee Community Bank Holdings, Inc., the parent company for Community Bank & Trust located in Ashland City, Tennessee, in its definitive agreement to sell to Reliant Bancorp, Inc. (Nasdaq: RBNC) for $37 million in an approximately 50% stock and 50% cash transaction.

    We represented Tennessee Community Bank Holdings, Inc., the parent company for Community Bank & Trust located in Ashland City, Tennessee,...
    Client Type: Private Company
  • We represented Mid-America Apartments, L.P., the operating partnership of Mid-America Apartment Communities, Inc., in a public offering of $250,000,000 of...
    Client Type: Public Company
  • We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

     

    We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc.,...
    Client Type: Public Company